Intolerant to imatinib or received prior imatinib therapy for treatment of advanced, metastatic, and/or unresectable GIST that resulted in disease progression.
Meet clinically acceptable local laboratory results.
You may not be if
Patients who are eligible for and capable of participating in and/or enrolled in an on-going bezuclastinib clinical trial.
Prior or known intolerance to sunitinib.
Patients who have previously participated in a bezuclastinib clinical trial.
Patients with persistent \> Grade 2 toxicities from prior therapy.
Known PDGFR driving mutations or known SDH deficiency.
